激智科技(300566.SZ)終止定增事項並申請撤回申請文件
格隆匯 1 月 8日丨激智科技(300566.SZ)公佈,公司於2021年1月8日召開第三屆董事會第十二次會議、第三屆監事會第十三次會議,審議通過了《關於公司終止向特定對象發行股票事項並申請撤回公司向特定對象發行股票申請文件的議案》等相關議案。
自公司此次向特定對象發行股票預案公佈以來,公司董事會、管理層與相關中介機構等一直積極推進此次向特定對象發行股票事項的各項工作。由於目前資本市場環境變化並綜合考慮公司實際情況、發展規劃等諸多因素,經公司審慎分析並與中介機構等反覆溝通論證,公司決定終止向特定對象發行股票事項並申請撤回公司向特定對象發行股票申請文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.